doc_id,table_id,row_index,ColumnA,ColumnB,ColumnC,ColumnD
WHO_TB_handbook_module5_pediatrics_2022,Table 3.1.,1,Target group,Preferred regimen,Alternative regimen(s),Notes
WHO_TB_handbook_module5_pediatrics_2022,Table 3.1.,2,HIV-negative children aged ≤2 years,3HR if paediatric fixed-dose combination (FDC) [a] available,"If paediatric FDC not available, use 6H (preferably dispersible tablets)",There is a lack of data on appropriate doses of rifapentine to allow use of 3HP in children aged <2 years There are no data for neonates; an expert should be consulted for advice on suitable TPT regimens
WHO_TB_handbook_module5_pediatrics_2022,Table 3.1.,3,HIV-negative children aged ≥2 years and ≤25 kg body weight,3HR if paediatric FDC [a] available,"If paediatric FDC not available, use 3HP or 6H","A paediatric formulation of rifapentine is not available A rifapentine 150 mg scored and dispersible formulation has been prioritized for development [b,c] A paediatric FDC for rifapentine and isoniazid is not planned for development"
WHO_TB_handbook_module5_pediatrics_2022,Table 3.1.,4,HIV-negative children >25 kg body weight,3HP using adult formulations,3HR using adult FDC 1HP using adult formulation (age ≥13 years),An adult isoniazid 300 mg/ rifapentine 300 mg scored FDC and an adult rifapentine 150 mg tablet are available
WHO_TB_handbook_module5_pediatrics_2022,Table 3.1.,5,Children living with HIV,6H (preferably using dispersible tablets),3HR for children on EFV-based ART 3HP for older children on EFV ART (and able to swallow tablets),"For more details on TPT regimens to use with ART, see Section 7.1 Data on 3HP in children on DTG are not yet available"
WHO_TB_handbook_module5_pediatrics_2022,Table 3.1.,6,Adolescents living with HIV,"3HP if on TDF, EFV, DTG or RALbased ART","1HP (age ≥13 years) if on TDF, EFV, DTG or RAL-based ART 6H","For more details on TPT regimens to use with ART, see Section 7.1 (including dose adjustments for 1HP with DTG or RAL)"